Compare Quest Diagnostics Inc (DGX) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs NICE Ltd — how do they compare? Quest Diagnostics Inc trades at $231.58 (market cap $25.48B), while NICE Ltd trades at $116.94 (market cap $6.81B). The key difference: Quest Diagnostics Inc is far larger — about 3.7× NICE Ltd's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while NICE Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and NICE Ltd for 15 Days on average.
| DGX | NICE | |
|---|---|---|
Market Cap | $25.48B | $6.81B |
Volume | 941,866 | 382,395 |
Sector | Health | Technology |
52-Week High | $247.45 | $137.68 |
52-Week Low | $173.49 | $83.15 |
Typical Hold Time | 56 Days | 15 Days |
Enterprise Value | $31.23B | $6.54B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
NICE trades at $116.83, up 0.35% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $124.20. The company reported strong Q2 2026 earnings, beating EPS estimates with $2.70 actual versus $2.63 expected, and was recently named a leader in the IDC MarketScape for contact center platforms (Business Wire, 2026-10-01). Revenue for 2025 was $2.95 billion with a net income margin of 20.78%.
The outlook is positive, supported by AI-driven growth and a reasonable valuation with a P/E of 17.08. However, risks include margin compression from increased investment and potential market volatility. Analyst sentiment is bullish with 12 buy ratings and no sells, but investors should monitor execution on AI initiatives and competitive pressures in the CX software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
